Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.53 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240098 | 0.92 | — | — | |
| SCHEMBL18396750 | 0.87 | — | — | |
| SCHEMBL2677621 | 0.78 | CRBN (0.71) | CRBNOR51E2FKBP5GAAKDM4E | |
| SCHEMBL747153 | 0.78 | — | — | |
| 2-Pyrrolidone SCHEMBL9100871 | 0.77 | OR51E2 (0.71) | CRBNOR51E2FKBP5GAAKDM4E | |
| SCHEMBL10764833 | 0.77 | — | — | |
| SCHEMBL6365823 | 0.72 | CRBN (0.85) | CRBNOR51E2FKBP5GAAKDM4E | |
| SCHEMBL42430 | 0.71 | — | — | |
| SCHEMBL10101154 | 0.71 | CRBN (0.42) | CRBNOR51E2FKBP5GAAMEN1 | |
| Thiomorpholine SCHEMBL17694294 | 0.69 | GAA (0.31) | CRBNOR51E2FKBP5GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120164039-A1 | PALLADIUM ION ADSORBENT AND METHODS FOR SEPARATING AND RECOVERING PALLADIUM USING IT | TOSOH CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120164039-A1 | PALLADIUM ION ADSORBENT AND METHODS FOR SEPARATING AND RECOVERING PALLADIUM USING IT | TOSOH CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164039-A1 | PALLADIUM ION ADSORBENT AND METHODS FOR SEPARATING AND RECOVERING PALLADIUM USING IT | PDCD10, PARK7, CCR10 | CRBN 955/4885OR51E2 165/4885FKBP5 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.